Ultragenyx Pharmaceutical Inc
NASDAQ:RARE

Watchlist Manager
Ultragenyx Pharmaceutical Inc Logo
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Watchlist
Price: 43.3 USD -2.08%
Market Cap: 4B USD
Have any thoughts about
Ultragenyx Pharmaceutical Inc?
Write Note

Ultragenyx Pharmaceutical Inc
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ultragenyx Pharmaceutical Inc
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Long-Term Investments
$203.1m
CAGR 3-Years
-11%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Long-Term Investments
$267m
CAGR 3-Years
-1%
CAGR 5-Years
15%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Long-Term Investments
$4.8B
CAGR 3-Years
410%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Long-Term Investments
$8.5B
CAGR 3-Years
14%
CAGR 5-Years
22%
CAGR 10-Years
34%
No Stocks Found

Ultragenyx Pharmaceutical Inc
Glance View

Market Cap
4B USD
Industry
Biotechnology

Ultragenyx Pharmaceutical Inc. emerges from the bustling biotech landscape as a company uniquely focused on addressing the unmet needs of rare and ultra-rare genetic diseases. Founded in 2010 by Dr. Emil Kakkis, who has been instrumental in the development of treatments for genetic conditions, Ultragenyx operates with a singular vision: to transform lives through the development and commercialization of novel therapies. The company works diligently at the intersection of biotechnology and medicine, where it utilizes advanced platforms, including gene therapy and biologics, to innovate treatments that specifically target the root causes of these rare diseases. By focusing on conditions with limited treatment options, Ultragenyx not only taps into niche markets but also helps forge new pathways in medical research. Financially, Ultragenyx capitalizes on its comprehensive portfolio of products and promising pipeline of candidates in various stages of development. The company's revenue model is primarily driven by the successful commercialization of its approved therapies, which provide life-changing benefits to patients with rare diseases. This revenue stream is augmented by strategic partnerships and collaborations, which help to mitigate costs and share risks associated with the high stakes of drug development. R&D investments are substantial, reflecting the company's commitment to innovation and long-term growth. In a sector characterized by high research costs and regulatory hurdles, Ultragenyx's targeted approach to niche diseases positions it as a potentially resilient player, with its revenues bolstered by a commitment to addressing critical patient needs.

RARE Intrinsic Value
63.72 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Ultragenyx Pharmaceutical Inc's Long-Term Investments?
Long-Term Investments
203.1m USD

Based on the financial report for Sep 30, 2024, Ultragenyx Pharmaceutical Inc's Long-Term Investments amounts to 203.1m USD.

What is Ultragenyx Pharmaceutical Inc's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
51%

Over the last year, the Long-Term Investments growth was 136%. The average annual Long-Term Investments growth rates for Ultragenyx Pharmaceutical Inc have been -11% over the past three years , 51% over the past five years .

Back to Top